Nissan Gravite 2026: The New Affordable 7-Seater MPV

Nissan Gravite 2026 MPV Announced as Affordable 7-Seater Option for Emerging Markets Nissan has officially unveiled the Gravite 2026, positioning it as a budget-friendly seven-passenger multi-purpose vehicle aimed at competing with models like the Toyota Avanza and Daihatsu Sigra in Southeast Asian markets. The announcement, made in mid-April 2026, highlights the vehicle’s modern design and advanced features despite its low price point. According to regional automotive reports, the Nissan Gravite 2026 is expected to be priced significantly below competing models, with some sources indicating a starting price of approximately IDR 105 million (around USD 6,500) in certain markets. This pricing strategy places it well under the cost of alternatives such as the Toyota Calya, potentially making it one of the most affordable seven-seater MPVs available. The vehicle is reported to include premium features typically found in higher-priced models, such as six airbags and a suite of modern driver assistance and infotainment technologies. These specifications have generated considerable interest among consumers looking for value-oriented family vehicles, particularly in Indonesia and neighboring countries where demand for affordable MPVs remains strong. Industry observers note that Nissan’s entry into this segment could intensify competition in the rapidly growing low-cost MPV market. The Gravite’s combination of spacious seating, safety features and contemporary styling may appeal to first-time car buyers and families seeking practical transportation without a premium price tag. While Nissan has not yet confirmed specific launch dates or exact pricing for all target markets, the Gravite 2026 is positioned as a strategic move to strengthen the automaker’s presence in emerging economies where affordability and functionality are key purchasing factors. The model is expected to undergo further evaluation for potential inclusion in Nissan’s global lineup, pending market response and regulatory approvals.